These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
    Author: Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE.
    Journal: J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):923-6. PubMed ID: 22791901.
    Abstract:
    BACKGROUND: Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11. METHODS: Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period. RESULTS: Both ligands displayed highly significant group discrimination and correlation of regional uptake. CONCLUSION: These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.
    [Abstract] [Full Text] [Related] [New Search]